Intervention

Linagliptin + metformin

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

3 shown

Effect of Low Dose Combination of Linagliptin + Metformin to Prevent DiabetesNCT04134650 · 2019-09-01

UNKNOWN

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With PrediabetesNCT03004612 · 2016-01-01

COMPLETED

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg BidNCT00915772 · 2009-06-01

COMPLETED

Common conditions

Insulin Resistance2 Prediabetic State2 Diabetes Mellitus, Type 21

Leading sponsors

Universidad de Guanajuato 2 Boehringer Ingelheim 1

Trial status mix

COMPLETED2

UNKNOWN1

Phase mix

PHASE32

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.